Ten years with biosimilar rhGH in clinical practice in Sweden – experience from the prospective PATRO children and adult studies

Ten years with biosimilar rhGH in clinical practice in Sweden – experience from the prospective PATRO children and adult studies

Abstract Background In 2007, Omnitrope® was the first biosimilar recombinant human growth hormone (rhGH) to be approved in Sweden for treatment in adults and children. Over 10 years’ safety and effectiveness data for biosimilar rhGH can now be presented. Methods PATRO Children and PATRO Adults are m...

Full description

Bibliographic Details
Main Authors: Elena Lundberg, Berit Kriström, Hichem Zouater, Anna Deleskog, Charlotte Höybye
Format: Article
Language:English
Published: BMC 2020-04-01
Series:BMC Endocrine Disorders
Subjects:
Recombinant growth hormone
Safety
Effectiveness
Antibodies
Omnitrope
Online Access:http://link.springer.com/article/10.1186/s12902-020-0535-4

Internet

http://link.springer.com/article/10.1186/s12902-020-0535-4

Similar Items